DailyIQ
|
DailyIQ
|
Last updatedUpdating…

VERA·Vera Therapeutics, Inc.

$30.14
+0.36 (+1.19%)
Pre-Market
High
$30.50
Open
$0.00
Market Cap
2.50B
52W High
$58.00
Low
$30.00
P. Close
$30.14
P/E
-
52W Low
$23.86
Fwd P/E
-7.05
DailyIQ Est.
$80.90
Inst. Own.
24.4%
Short Interest
16.59%
Days to Cover
7.2
NewEarnings release, scored · filed Nov 5, 2026tone -11.4 vs prior release · 105 lines scoredSee the breakdown
Technical Score (1D)
69
BULLISH
News Sentiment
58
BULLISH
On Nov 6, Vera Therapeutics held a Q3 2026 earnings call, during which senior executives reviewed the quarter’s financial results and business highlights for the period ended September 30. On Nov 5, the company announced its Q3 2026 financial results, reporting $10.3 million in net product revenue from the early U.S. launch of TRUTAKNA. On Nov 5, Vera also highlighted accelerated FDA approval on July 7 and a successful sBLA submission for full approval in adults with primary IgAN. On Nov 5, clinical data presented at ASN Kidney Week 2026 showed a 76 % reduction in kidney disease progression versus placebo, reinforcing the product’s therapeutic value. On Nov 6, the call’s senior leadership emphasized pipeline progress and liquidity maintenance, noting no major guidance changes or surprises. On Nov 6, the webcast concluded with a Q&A session addressing analyst inquiries about future outlook and capital allocation.
LOW TARGET
$34 +11.5%
1 analysts
MEAN TARGET
$74 +141.9%
11 analysts
HIGH TARGET
$100 +227.9%
10 analysts
PRICE RANGE
$34.00 - $100.00
SB / B / H / S / SS
7/10/3/1/1
DAILYIQ EST.
$80.90 (+165.2%)
Bought (1Y)
0 shares
$0
Sold (1Y)
37,000 shares
$1.3M
Fordyce MarshallPRESIDENT AND CEO
Option Exercise18,500 shares2026-09-15
Fordyce MarshallPRESIDENT AND CEO
Sell18,500 shares2026-09-15
Fordyce MarshallPRESIDENT AND CEO
Option Exercise18,500 shares2026-09-15
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
Option Exercise5,000 shares2026-09-11
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
Option Exercise5,000 shares2026-09-11
View full insider trading history →
55/ 100
Neutral / mixed
Overall: Neutral
✕Negative operating cash flow
✓Manageable liabilities relative to assets
✓Analyst target above current price
Current Ratio
13.64x
Debt / Equity
0.12x
Return on Equity
-49.6%
View full financials →

EPS

EstBeatMiss
$-1.73$-1.56$-1.39$-1.22$-1.05Q3'25Q3'26Q4'26
QtrEstActual+/−
Q4'26$-1.52 - -
Q3'26$-1.65$-1.30+21.3%
Q3'25$-1.13$-1.26-11.7%

Revenue

EstBeatMiss
$-3M$3M$9M$14M$20MQ3'25Q3'26Q4'26
QtrEstActual+/−
Q4'26$17M - -
Q3'26 - $10M -
Q3'25 - $0 -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

VERA Stock Snapshot

BULLISH69/100
$30.50+$0.36 (1.2%)
Market cap
2.50B
Day range
$30.00 – $30.50
News sentiment
58/100 · Neutral
Analyst target
$73.79 (+141.9%)
Consensus
Buy · 22 analysts
52-week range+27.8% off low · -47.4% from high
$23.86$58.00
Price $30.50 DailyIQ Est. $80.90

Price is in the lower half of its 52-week range, and the momentum read backs that positioning up. Position sizing matters more than usual in a name this size, where volatility is structural.

Behaviour On Record

What VERA's own history says about today's numbers

Realized volatility (21d)
57.2% 42nd pct
Below its peak
-42.9%
vs 200-day average
-14.6%
Up days (1y)
47%

Vera Therapeutics, Inc. is currently running 57.2% annualised volatility over the last 21 sessions. Measured against VERA's own 5 years of daily returns rather than a market-wide average, that is the 42nd percentile — close to its own typical level, against a typical reading of 60.3%.

VERA is trading -42.9% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -52.7%, and the deepest was -56.4% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -14.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 32nd percentile — close to the gap it normally carries. Over the past year VERA closed higher on 47% of sessions, and it is currently 1 session into a falling streak.

On November specifically: over 5 years of records, VERA finished the month higher 4 of 5 times, with a median return of +24.0% and an average of +32.2%. Its strongest month historically has been November at +32.2% on average, its weakest April at -7.0%.

Overnight risk is measurable too: VERA has opened more than 2% away from the prior close in 325 of 1,371 sessions (23.7% of the time), with the largest gaps running +11.2% and -12.8%.

All figures computed from 1,373 daily closes between 2021-05-14 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against VERA's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of VERA's sector?

Vera Therapeutics, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, VERA ranks 9th of 15 tracked industries, weakening.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
100
Industry rank
#9 of 15

Analyst Consensus Estimates

What do analysts expect VERA to earn?

Analysts expect Vera Therapeutics, Inc. to earn -$6.25 per share in the fiscal year ending Dec 2026 and $2.92 in the fiscal year ending Dec 2029, from 3 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026-$1.61-$1.80 to -$1.399$4M13
Dec 2026-$1.54-$2.18 to -$1.219$17M13
Mar 2027-$1.35-$1.51 to -$1.194--
Jun 2027-$1.21-$1.35 to -$1.124--
Sep 2027-$1.04-$1.13 to -$0.984--
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$6.25-$7.23 to -$5.7710$25M12
Dec 2027-$4.25-$6.72 to -$2.2310$234M12
Dec 2028-$1.15-$2.35 to $0.494--
Dec 2029$2.92$0.15 to $5.213--

Analyst Rating Changes

Are analysts turning bullish or bearish on VERA?

Leerink Partners most recently initiated coverage on Vera Therapeutics, Inc. to Market Perform on Oct 12, 2026 with a price target of $34. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Leerink Partners: Market Perform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026Leerink PartnersInitiatedMarket Perform$34
Sep 8, 2026JP MorganMaintainedOverweight$76 → $83
Aug 17, 2026WedbushReiteratedNeutral$34
Aug 12, 2026HC Wainwright & Co.MaintainedBuy$125 → $90
Aug 11, 2026WedbushMaintainedNeutral$43 → $34
Jul 8, 2026TD CowenMaintainedBuy$73 → $78
Jul 8, 2026GuggenheimMaintainedBuy$56 → $76
Jul 8, 2026WedbushMaintainedNeutral$35 → $43
Jul 8, 2026HC Wainwright & Co.MaintainedBuy$110 → $125
Jul 7, 2026B of A SecuritiesMaintainedBuy$65 → $70
May 15, 2026Evercore ISI GroupMaintainedOutperform$95 → $91
Mar 11, 2026Wolfe ResearchUpgradePeer Perform → Outperform$88

Corporate Stakes

Which companies own a stake in VERA?

0.29%held by GOOGL

Alphabet Inc. reports a stake in Vera Therapeutics, Inc. on SEC Form 13F: 241.3K shares, about 0.29% of the company, worth $10.4M at the end of Q2 2026. At today's price that stake is worth $7.4M, about 0.00% of GOOGL's own market value.

Holder
GOOGL
Shares held
241.3K
Stake
0.29%
Value
$10.4M
HolderLast quarterShares% of VERAValue at filingValue nowChange
Alphabet Inc. GOOGLUnchanged241.3K0.29%$10.4M$7.4M-28.9%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

Earnings Release, Scored

What did Vera Therapeutics, Inc.'s latest earnings release say?

Filed Nov 5, 2026 · SEC Form 8-K, Exhibit 99

Tone55.7/ 100-11.4 vs prior release
Hedging words1.64per 100 words+0.85 vs prior release
Tone, last 3 releasesScale 50–75

Most important lines

  1. 1

    Research and development expenses were $41.3 million, compared with $56.5 million in the prior-year quarter.

    New this quarter
  2. 2

    The decrease was primarily due to a reduction in contract manufacturing expenses, as manufacturing costs for TRUTAKNA commercial supply, which were previously categorized as research and development expense, have been capitalized as inventory since its accelerated approval on July 7, 2026.

    New this quarter
  3. 3

    For the quarter ended September 30, 2026, Vera Therapeutics reported net product revenue of $10.3 million, compared with the prior year period during which no product revenue was reported.

    New this quarter

Scores describe the release's wording. They are not a forecast.

Read all 105 scored lines →

ETF holders

ETFs holding VERA

Top ETF holdersWeight

News & sentiment

What is the news saying about VERA?

VERA rose 1.7% over the month to Nov 5. News tone held between 42 and 86 from Oct 8 to Oct 23, then dropped to 46 on Nov 2.

Daily close and news tone, Oct 5 to Nov 5
$28$30$32Oct 5Oct 6Oct 7Oct 8: tone 42Oct 9: tone 62Oct 12: tone 42Oct 13Oct 14Oct 15Oct 16Oct 19Oct 20: tone 45Oct 21Oct 22: tone 79Oct 23: tone 87Oct 26Oct 27Oct 28Oct 29Oct 30Nov 2: tone 46Nov 3Nov 4Nov 5: tone 40Oct 5News toneNov 5123
  1. Oct 12 -7.2%same day: Leerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price Target
  2. Oct 23 -7.3%same day: Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
  3. Oct 27 +6.2%
Latest stories naming Vera Therapeutics

Technical analysis

How strong is VERA's momentum right now?

On the daily chart VERA ranks at the 69th percentile for momentum against 1,060 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling VERA?

38 of the 71 tracked managers added to VERA in their latest 13F and 30 trimmed. Together they own 24.1% of the company, worth $808.0M. State Street and Vanguard Capital Management alone hold 8.4%.

38adding30trimming3unchanged
Largest holders by stake, latest 13FBar = share of VERA
  1. 1State Street Corp5.07%
    $178.0M positionAdded 23.3% last quarter
  2. 2Vanguard Capital Management LLC3.36%
    $118.2M positionAdded 2.7% last quarter
  3. 3Pictet Asset Management Holding SA2.25%
    $59.4M positionAdded 47.2% last quarter
  4. 4Deutsche Bank AG1.35%
    $47.3M positionAdded 107.0% last quarter
  5. 5Qube Research & Technologies Ltd1.32%
    $46.5M positionAdded 99.9% last quarter
  6. 6Woodline Partners LP1.22%
    $43.0M positionUnchanged last quarter
  7. 7American Century Companies Inc1.06%
    $37.2M positionAdded 18.9% last quarter
  8. 8Dimensional Fund Advisors LP0.79%
    $21.0M positionAdded 23.2% last quarter
  9. 9Vanguard Portfolio Management LLC0.78%
    $27.6M positionAdded 16.3% last quarter
  10. 10Voya Investment Management LLC0.78%
    $27.6M positionAdded 121.2% last quarter
Full holdings history

Discover more

How has VERA done against its peers?

Over the six months to Nov 5, VERA returned −11.5%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +418.8%.

Change since May 5, through Nov 5
−200%0%+200%+400%+600%May 5JunJulAugSepOctNov 5MRNA +418.8%VERA −11.5%INSM −21.9%